Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,875 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06900595RecruitingPhase 2
Cabozantinib with immunotherapy for advanced adrenal cancer
This trial tests adding the targeted drug cabozantinib to the immunotherapy cemiplimab for people with advanced adrenocortical carcinoma that cannot be removed by surgery or has spread. It checks if the combination works better than cabozantinib alone.
La Jolla, CaliforniaAges 12 years+ - NCT04297605RecruitingPhase 1
Pembrolizumab plus chemotherapy for advanced lung cancer
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
Rochester, New YorkAges 18 years+ - NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Phoenix, ArizonaAges 18 years+ - NCT05382728RecruitingPhase 3
Test drug for EGFR-mutant lung cancer without prior treatment
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
Changsha, HunanAges 18–80 - NCT05599412Recruiting
Tracking safety of Lorviqua in ALK-positive lung cancer
This study is collecting real-world safety information about Lorviqua (lorlatinib) in adults in Korea who have ALK-positive metastatic non-small cell lung cancer. It helps monitor side effects and safe use after the medicine is already on the market.
SeoulAges 18 years+ - NCT06359847RecruitingPhase 2
ST-1898 for advanced thyroid cancer that no longer responds to iodine therapy
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07003321RecruitingPhase 2
Testing HRS-4508 for advanced non-small cell lung cancer
This trial tests an experimental drug called HRS-4508 for people with advanced non-small cell lung cancer that has stopped responding to standard treatments or cannot tolerate them. The goal is to see if it can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06479759RecruitingPhase 2
LM-108 with sintilimab for advanced lung cancer
This trial tests a new antibody combination for non-small cell lung cancer that has spread or come back. It may help people whose cancer stopped responding to immunotherapy or who haven't had treatment yet.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
La Mesa, CaliforniaAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Daphne, AlabamaAges 18 years+ - NCT07227025RecruitingPhase 1/Phase 2
Study of amivantamab and olomorasib for KRAS G12C lung cancer
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT03947385RecruitingPhase 1/Phase 2
First drug test for metastatic uveal melanoma with specific gene changes
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
Los Angeles, CaliforniaAges 18 years+ - NCT05192798RecruitingPhase 2
Albumin-bound chemo plus anti-blood-vessel drugs for TNBC
This Phase 2 study tests a chemotherapy called albumin-bound paclitaxel combined with medicines that block new blood vessel growth (antiangiogenic agents) for women with recurrent or metastatic triple-negative breast cancer. It aims to see whether this combination can better control cancer when it comes back or has spread.
Bengbu, AnhuiAges 18–80 - NCT05394337RecruitingPhase 1/Phase 2
Immunotherapy before bladder surgery for cisplatin-ineligible patients
This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.
Houston, TexasAges 18 years+ - NCT05733598RecruitingPhase 2
RP2 plus standard treatment for advanced liver or bile cancers
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Beverly Hills, CaliforniaAges 18 years+ - NCT05760378RecruitingPhase 3
Famitinib plus immunotherapy for advanced triple-negative breast cancer
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06313541RecruitingPhase 2
Adaptive radiation with immunotherapy for advanced lung cancer
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
ShanghaiAges 18 years+ - NCT06581419RecruitingPhase 1/Phase 2
Testing IAP0971 in advanced solid tumors and lung cancer
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT06855771RecruitingPhase 2
Study of an oral drug for MTAP-deleted advanced lung cancer
This study tests an experimental oral medication (navlimetostat) for people with advanced lung cancer whose tumors have a specific genetic change called an MTAP deletion. It’s for those whose cancer has progressed after earlier treatments.
Anchorage, AlaskaAges 18 years+ - NCT07054307RecruitingPhase 1
Study of MRG003 plus HX008 for EGFR-positive penile cancer
This trial tests two drugs, MRG003 and HX008, as a first treatment for men with EGFR-positive penile squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if the combination shrinks tumors or delays growth.
Chengdu, SichuanAges 18 years+ - NCT07114939RecruitingPhase 1
A new pet scan for pancreatic neuroendocrine tumors
This study is testing a special type of PET/CT scan using a tracer called FTT to see if it can better find and track pancreatic neuroendocrine tumors that have spread or cannot be removed by surgery. The goal is to improve imaging for people with this type of cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07288073RecruitingPhase 2
TIL Therapy for Advanced Skin Cancer Patients
This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.
Boston, MassachusettsAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,875 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.